Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Reggio Emilia, Italy Clinical Trials

A listing of Reggio Emilia, Italy clinical trials actively recruiting patients volunteers.

RESULTS

Found (11) clinical trials

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Patients eligible for the study will receive 6 courses (q 28 days) of the DEVEC combination, according to the following schedule: DE: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 it is reduced to ...

Phase

0.0 miles

Learn More »

Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia

This is a phase II multicenter, non-comparative, open label study for high risk previously treated patients with CLL, requiring therapy, aimed at evaluating the efficacy of the Ofatumumab and Ibrutinib combination.

Phase

0.0 miles

Learn More »

Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients. Quality of Life (QoL) is mainly deteriorated by anemia and by the limitations associated with thrombocytopenia, neutropenia and transfusion dependence. The only available treatment ...

Phase

0.0 miles

Learn More »

A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

This is a prospective, multicenter, single arm, phase II trial in elderly patients ( 70 years) affected by DLBCL defined as frail according to CGA and previously untreated. The primary endpoint is to evaluate the efficacy of the R2 (Revlimid+Rituximab) combination in first line DLBCL patients not candidate for the ...

Phase

0.0 miles

Learn More »

rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets

Intracerebral hemorrhage (ICH) is the deadliest, most disabling, and least treatable form of stroke. Approximately 40% of patients die within 1 month of ICH onset, and two-thirds of survivors never regain functional independence. Though guidelines for supportive care exist, there is currently no treatment that has been shown in a ...

Phase

0.0 miles

Learn More »

Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC

In spite of the superiority of single agent over best supportive care in second-line NSCLC, the prognosis of these patients remains poor with a median survival of 6-7 months, justifying the evaluation of new regimens in this setting. An open question in the second-line treatment of NSCLC remains the possible ...

Phase

1.53 miles

Learn More »

Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias

The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as: 1. Idiopathic Hypereosinophilic Syndrome (secondary HES), defined as a peripheral blood eosinophilia greater than 1,500 cells/µL for longer than 6 months, absence of other apparent aetiologies for ...

Phase

1.53 miles

Learn More »

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

NIVES study is an ongoing phase II, single arm, multicenter study. In this trial pts received SBRT to one non-brain measurable lesion and concomitant NIVOLUMAB, an anti-programmed cell death (PD-1). Combining SBRT with NIVO may enhance the antitumor immune responses and improve clinical outcomes, how it was demonstrated for other ...

Phase

2.76 miles

Learn More »

Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer

Women with histologically confirmed HER2-positive breast cancer with locally advanced, inflammatory,or early stage tumor (either greater than 2 cm in diameter or node positive) with no evidence of metastatic disease.

Phase

2.76 miles

Learn More »

Study Maintenance Regorafenib vs Placebo no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

Randomized, double-blind, placebo-controlled, multicenter Phase-II study. Approximately 120 subjects with CR/PR/SD after platinum compounds and fluoropyrimidines based regimens: up to 6 cycles of cisplatin and 5-fluorouracil or capecitabine, up to 12 cycles of FOLFOX, up to 8 cycles of XELOX, will be randomly assigned (1:1 ratio) to one of the ...

Phase

2.76 miles

Learn More »